ArticleJournal of virology2025
Design of antibody structure-guided epitope vaccines
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From legacy to innovation: A comprehensive review of vaccine platforms against viral infections.Virus research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The severe damage caused by public health emergencies in recent years indicates that epitope identification and vaccine development remain potential strategies to stop viral epidemics. Despite challenges such as comprehensive virus analysis, computer simulations and antibody-based reverse vaccinology can rapidly localize antigenic epitopes without the need to resolve protein functions, thereby supporting vaccine design. In previous studies, we developed a strategy for peptide vaccine design based on simulated epitopes for tilapia lake virus (TiLV). To further improve vaccine immunogenicity and capitalize on the significance of antibodies for epitope screening, this study presents a structural modification strategy based on antigen-antibody docking for reverse vaccinology in conjunction with single amino acid mutagenesis inducing a robust immune response in tilapia. A high-affinity scFv1 was obtained through screening from the constructed single-chain antibody fragment (scFv) library targeting TiLV. Subsequently, the key dominant epitope IMPORTANCE: Public health emergencies pose significant threats to both human and environmental health, and the rapid control of emerging diseases often remains challenging due to their unknown characteristics. In this context, vaccines have historically been instrumental in the fight against major diseases, with epitope vaccines emerging as a preferred approach due to their precision and efficacy. In previous studies, we developed a strategy for peptide vaccine design based on simulated epitopes for tilapia lake virus (TiLV). To further improve vaccine immunogenicity and capitalize on the significance of antibodies for epitope screening, this study presents a structural modification strategy based on antigen-antibody docking for reverse vaccinology in conjunction with single amino acid mutagenesis inducing a robust immune response in tilapia. We believe that our findings are highly relevant to the field and contribute to the ongoing efforts to combat public health threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.